Advanced Search

 

Study ID Status Title Patient Level Data
LPT111111 Active, Not Recruiting LPT 111111- A Single-arm, Multicenter Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin bound Paclitaxel (nab-Paclitaxel or ABRAXANE®) and Lapatinib (TYKERB®) in Women With No More Than One Prior Treatment for ErbB2 Overexpressing Metastatic Breast Cancer
MAB104954 Completed A study to optimise the propranolol block model for assessment of the pharmacological activity of bronchodilators in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
MAB104958 Completed A study to assess the pharmacokinetics of single escalating doses of inhaled GSK961081 DPI (a dual pharmacophore) in healthy subjects (Part 1) and a randomised, double-blind, double dummy, crossover (incomplete block) study to assess the safety, tolerability, pharmacodynamics (pulmonary and systemic) and pharmacokinetics of 14 days dosing with inhaled GSK961081 DPI compared with placebo and tiotropium plus salmeterol in patients with COPD (Part 2) Study Listed on ClinicalStudyDataRequest.com
MAB108115 Completed A randomised, double-blind, dose escalating study in healthy volunteers to assess the safety, tolerability, extra pulmonary pharmacodynamics and pharmacokinetics of single doses of GSK961081 (succinate salt) Study Listed on ClinicalStudyDataRequest.com
MAB110123 Completed A randomized, double-blind, crossover study to investigate the bronchodilatation post-inhalation of GSK961081 alone and with the addition of cumulative doses of short acting bronchodilators (salbutamol and ipratropium bromide) in patients with COPD Study Listed on ClinicalStudyDataRequest.com
MAB110553 Completed A study to investigate the relative pharmacological activity of aninhaled B2-agonist/anticholinergic dual pharmacophore inhealthy volunteers Study Listed on ClinicalStudyDataRequest.com
MAD103894 Completed A 28 day, Polysomnographic and Subjective Assessment of GW679769 for the Treatment of Primary Insomnia: A Randomized, Double-blind, Parallel-Group, Placebo-Controlled Trial.
MAD105514 Completed A randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of GW679769 on polysomnographic sleep recordings, subjective sleep assessment, and daytime cognitive function in elderly and non-elderly subjects with primary insomnia
MAD105516 Completed A randomized, double-blind, placebo-controlled, crossover study to evaluate the effects of morning administration of GW679769 (10mg and 30 mg) on polysomnograph sleep recordings, subjective sleep assessment, daytime cognition and psychomotor function in subjects with primary insomnia
MAG103114 Completed A single-blind, single dose, placebo controlled, first time in human study to assess the safety, tolerability and pharmacokinetics of ascending doses of GSK249320 in healthy volunteers Study Listed on ClinicalStudyDataRequest.com
MD7108238 Completed A placebo-controlled, randomized, dose rising study to evaluate the safety, tolerability and pharmacokinetics of single and repeat ocular doses of pazopanib in healthy adult and elderly subjects.
MD7108240 Completed A double-masked, randomized, parallel-group study to investigate the pharmacodynamics, safety, and systemic pharmacokinetics of pazopanib drops, administered for 28 days to adult subjects with neovascular age-related macular degeneration.
MD7110861 Completed An open-label, two-period, fixed-sequence study in Healthy volunteers to evaluate the effects of repeat oral dosing of ketoconazole on the pharmacokinetics of a single dose of pazopanib (GW786034) administered as eye drops
MD7111396 Completed An extension study to protocol MD7108240: pazopanib eye drops in subjects with neovascular age-related macular degeneration
MEE103219 Completed A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years (Study MEE103219) Study Listed on ClinicalStudyDataRequest.com
MEE103226 Completed A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Provide a Preliminary evaluation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Intravenous anti-human interleukin-5 (mepolizumab, 750mg and 1500mg) in the treatment of Eosinophilic Oesophagitis in Adults Study Listed on ClinicalStudyDataRequest.com
MEK111054 Completed An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor GSK1120212 in Subjects with Solid Tumors or Lymphoma
MET111516 Completed An Open-label, Randomized, Two-way Balanced Crossover Study to Investigate the Bioavailability of two forms ofGSK1363089 in Subjects with Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MET111643 Completed A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects with Metastatic Gastric Cancer Study Listed on ClinicalStudyDataRequest.com
MET111644 Completed A Phase 2 Study of the c-Met RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects with Papillary Renal-Cell Carcinoma Study Listed on ClinicalStudyDataRequest.com
MET111646 Completed A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Study Listed on ClinicalStudyDataRequest.com
MET111647 Completed A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MET111648 Completed A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects with Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MHE104317 Recruiting 104317: An Open-Label Compassionate Use access and Long-Term Access Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome 201956: A Long-term Access Programme for Subjects with Severe Asthma who Participated in a GSK-sponsored Mepolizumab Clinical Study
MKC101614 Completed A 28-day, randomised, double-blind, placebo-controlled study to assess the safety, tolerability, anti-inflammatory effect and steady-state pharmacokinetics of SB-681323 7.5 mg per day in patients with chronic obstructive pulmonary disease.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.